ALTERNATIVES TO STATINS IN THE TREATMENT OF HYPERCHOLESTEROLEMIA
Abstract
Hypercholesterolemia is one of the main modifiable risk factors for cardiovascular disease. Elevated levels of LDL (low-density lipoprotein) cholesterol lead to the development of atherosclerosis and cardiovascular complications. Statins are the mainstay of hypercholesterolemia therapy, but in some patients, therapeutic goals are not achieved or side effects occur. It is necessary to develop alternatives to statins for the treatment of hypercholesterolemia. Drugs that act on other stages of cholesterol synthesis are being sought. Publications covering observational studies, randomized controlled trials (RCTs), and meta-analyses on alternative therapies for hypercholesterolemia to statin treatment were analyzed. The following were described: cholesterol absorption inhibitor (ezetimibe), ATP citrate lyase inhibitor (bempedoic acid), PCSK9 inhibitors (evolocumab, alirocumab) , siRNA against PCSK9 (inclisiran), ANGPTL3 inhibitors (evinacumab), ANGPTL4, ANGPTL8 and ANGPTL3/8 complex inhibitors, fibrates and nutraceuticals (plant sterols, fermented red yeast rice extract (Red Yeast Rice, RYR) , berberine). The impact of these drugs on patients' lipid profiles and cardiovascular risk was discussed. Attention was also drawn to the need for individualization of hypercholesterolemia therapy.
Aim of this study: The objective of this study is to summarize the latest reports on alternative therapies for hypercholesterolemia to statins.
Materials and methods: A literature review was conducted using the professional PubMed database. Searches included combinations of the keywords: “hypercholesterolemia,” “ezetimibe,” “bempedoic acid,” and “PCSK9 inhibitors.”
References
Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, Chapman MJ, De Backer GG, Delgado V, Ference BA, Graham IM, Halliday A, Landmesser U, Mihaylova B, Pedersen TR, Riccardi G, Richter DJ, Sabatine MS, Taskinen MR, Tokgozoglu L, Wiklund O; ESC Scientific Document Group. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020 Jan 1;41(1):111-188. doi: 10.1093/eurheartj/ehz455. Erratum in: Eur Heart J. 2020 Nov 21;41(44):4255. doi: 10.1093/eurheartj/ehz826.
Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, Braun LT, de Ferranti S, Faiella-Tommasino J, Forman DE, Goldberg R, Heidenreich PA, Hlatky MA, Jones DW, Lloyd-Jones D, Lopez-Pajares N, Ndumele CE, Orringer CE, Peralta CA, Saseen JJ, Smith SC Jr, Sperling L, Virani SS, Yeboah J. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019 Jun 18;139(25):e1082-e1143. doi: 10.1161/CIR.0000000000000625.
Kamer R. Medical Care for Undocumented Immigrants. JAMA. 2018 Apr 24;319(16):1727. doi: 10.1001/jama.2018.1369.
Righetto R, Fracchiolla F, Widesott L, Lorentini S, Dionisi F, Rombi B, Scartoni D, Vennarini S, Schwarz M, Farace P. Technical challenges in the treatment of mediastinal lymphomas by proton pencil beam scanning and deep inspiration breath-hold. Radiother Oncol. 2022 Apr;169:43-50. doi: 10.1016/j.radonc.2022.02.015.
Hong SJ, Lee YJ, Lee SJ, Hong BK, Kang WC, Lee JY, Lee JB, Yang TH, Yoon J, Ahn CM, Kim JS, Kim BK, Ko YG, Choi D, Jang Y, Hong MK; LODESTAR Investigators. Treat-to-Target or High-Intensity Statin in Patients With Coronary Artery Disease: A Randomized Clinical Trial. JAMA. 2023 Apr 4;329(13):1078-1087. doi: 10.1001/jama.2023.2487.
Wei Z, Wang F, Zhang L, Dai W. Clinical Efficacy of Ezetimibe Combined with Rosuvastatin in the Treatment of Patients with Primary Hypercholesterolemia Inadequately Controlled by Statin Therapy. Br J Hosp Med (Lond). 2024 Nov 30;85(11):1-13. doi: 10.12968/hmed.2024.0457.
Vinci P, Panizon E, Tosoni LM, Cerrato C, Pellicori F, Mearelli F, Biasinutto C, Fiotti N, Di Girolamo FG, Biolo G. Statin-Associated Myopathy: Emphasis on Mechanisms and Targeted Therapy. Int J Mol Sci. 2021 Oct 28;22(21):11687. doi: 10.3390/ijms222111687.
Menzin J, Aggarwal J, Boatman B, Yu J, Stern K, Harrison DJ, Patel JG. Ezetimibe Use and LDL-C Goal Achievement: A Retrospective Database Analysis of Patients with Clinical Atherosclerotic Cardiovascular Disease or Probable Heterozygous Familial Hypercholesterolemia. J Manag Care Spec Pharm. 2017 Dec;23(12):1270-1276. doi: 10.18553/jmcp.2017.16414.
Zhan S, Tang M, Liu F, Xia P, Shu M, Wu X. Ezetimibe for the prevention of cardiovascular disease and all-cause mortality events. Cochrane Database Syst Rev. 2018 Nov 19;11(11):CD012502. doi: 10.1002/14651858.CD012502.pub2.
Fras Z, Mikhailidis DP. Have We Learnt all from IMPROVE-IT? Part I. Core Results and Subanalyses on the Effects of Ezetimibe Added to Statin Therapy Related to Age, Gender and Selected Chronic Diseases (Kidney Disease, Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease). Curr Vasc Pharmacol. 2021;19(5):451-468. doi: 10.2174/1570161118999200727224946.
Manolis AA, Manolis TA, Mikhailidis DP, Manolis AS. Are We Using Ezetimibe As Much As We Should? Biomark Insights. 2024 May 31;19:11772719241257410. doi: 10.1177/11772719241257410.
Wang Y, Zhan S, Du H, Li J, Khan SU, Aertgeerts B, et al. Safety of ezetimibe in lipid-lowering treatment: systematic review and meta-analysis of randomised controlled trials and cohort studies. BMJ Medicine. 2022;1:e000134. doi: 10.1136/bmjmed-2022-000134.
Ferri N, Colombo E, Corsini A. Bempedoic Acid, the First-in-Class Oral ATP Citrate Lyase Inhibitor with Hypocholesterolemic Activity: Clinical Pharmacology and Drug-Drug Interactions. Pharmaceutics. 2024 Oct 26;16(11):1371. doi: 10.3390/pharmaceutics16111371.
Duarte Lau F, Giugliano RP. Adenosine Triphosphate Citrate Lyase and Fatty Acid Synthesis Inhibition: A Narrative Review. JAMA Cardiol. 2023 Sep 1;8(9):879-887. doi: 10.1001/jamacardio.2023.2402.
Yang J. Bempedoic acid for the treatment of hypercholesterolemia. Expert Rev Cardiovasc Ther. 2020 Jul;18(7):373-380. doi: 10.1080/14779072.2020.1782744.
Nicholls SJ, Nelson AJ, Lincoff AM, Brennan D, Ray KK, Cho L, Menon V, Li N, Bloedon L, Nissen SE. Impact of Bempedoic Acid on Total Cardiovascular Events: A Prespecified Analysis of the CLEAR Outcomes Randomized Clinical Trial. JAMA Cardiol. 2024 Mar 1;9(3):245-253. doi: 10.1001/jamacardio.2023.5155. Erratum in: JAMA Cardiol. 2024 Jul 1;9(7):674. doi: 10.1001/jamacardio.2024.1279.
Ridker PM, Lei L, Louie MJ, Haddad T, Nicholls SJ, Lincoff AM, Libby P, Nissen SE; CLEAR Outcomes Investigators. Inflammation and Cholesterol as Predictors of Cardiovascular Events Among 13 970 Contemporary High-Risk Patients With Statin Intolerance. Circulation. 2024 Jan 2;149(1):28-35. doi: 10.1161/CIRCULATIONAHA.123.066213.
Jeswani BM, Sharma S, Rathore SS, Nazir A, Bhatheja R, Kapoor K. PCSK9 Inhibitors: The Evolving Future. Health Sci Rep. 2024 Oct 30;7(11):e70174. doi: 10.1002/hsr2.70174.
Chlebus K, Cybulska B, Dobrowolski P, Romanowska-Kocejko M, Żarczyńska-Buchowiecka M, Gilis-Malinowska N, Stróżyk A, Borowiec-Wolna J, Pajkowski M, Bobrowska B, Rajtar-Salwa R, Kwapiszewska A, Waluś-Miarka M, Chmara M, Gałąska R, Małecki M, Zdrojewski T, Gruchała M. Effectiveness and safety of PCSK9 inhibitor therapy in patients with familial hypercholesterolemia within a therapeutic program in Poland: Preliminary multicenter data. Cardiol J. 2022;29(1):62-71. doi: 10.5603/CJ.a2022.0003.
Garwood CL, Cabral KP, Brown R, Dixon DL. Current and emerging PCSK9-directed therapies to reduce LDL-C and ASCVD risk: A state-of-the-art review. Pharmacotherapy. 2025 Jan;45(1):54-65. doi: 10.1002/phar.4635.
Guedeney P, Giustino G, Sorrentino S, Claessen BE, Camaj A, Kalkman DN, Vogel B, Sartori S, De Rosa S, Baber U, Indolfi C, Montalescot G, Dangas GD, Rosenson RS, Pocock SJ, Mehran R. Efficacy and safety of alirocumab and evolocumab: a systematic review and meta-analysis of randomized controlled trials. Eur Heart J. 2022 Feb 12;43(7):e17-e25. doi: 10.1093/eurheartj/ehz430.
Marrs JC, Anderson SL. Inclisiran for the treatment of hypercholesterolaemia. Drugs Context. 2024 Nov 28;13:2023-12-3. doi: 10.7573/dic.2023-12-3.
Hardy J, Niman S, Pereira E, Lewis T, Reid J, Choksi R, Goldfaden RF. A Critical Review of the Efficacy and Safety of Inclisiran. Am J Cardiovasc Drugs. 2021 Nov;21(6):629-642. doi: 10.1007/s40256-021-00477-7.
Ray KK, Raal FJ, Kallend DG, Jaros MJ, Koenig W, Leiter LA, Landmesser U, Schwartz GG, Lawrence D, Friedman A, Garcia Conde L, Wright RS; ORION Phase III investigators. Inclisiran and cardiovascular events: a patient-level analysis of phase III trials. Eur Heart J. 2023 Jan 7;44(2):129-138. doi: 10.1093/eurheartj/ehac594.
Basit J, Ahmed M, Singh P, Ahsan A, Zulfiqar E, Iqbal J, Fatima M, Upreti P, Hamza M, Alraies MC. Safety and Efficacy of Inclisiran in Hyperlipidemia: An Updated Meta-Analysis of Randomised Controlled Trials. Endocrinol Diabetes Metab. 2025 Mar;8(2):e70039. doi: 10.1002/edm2.70039.
Raal F, Durst R, Bi R, Talloczy Z, Maheux P, Lesogor A, Kastelein JJP; ORION-5 Study Investigators. Efficacy, Safety, and Tolerability of Inclisiran in Patients With Homozygous Familial Hypercholesterolemia: Results From the ORION-5 Randomized Clinical Trial. Circulation. 2024 Jan 30;149(5):354-362. doi: 10.1161/CIRCULATIONAHA.122.063460.
Cheng Z, Gao M, Liu Y, Yan W, Zhang Z, Jiao N, Li C. Safety and efficacy of inclisiran in treating hypercholesterolemia: A systemic review and meta-analysis. Nutr Metab Cardiovasc Dis. 2025 May;35(5):103779. doi: 10.1016/j.numecd.2024.10.017.
Gao Y, Zhang B, Yang J. Evinacumab for the treatment of homozygous familial hypercholesterolemia. Expert Rev Clin Pharmacol. 2022 Feb;15(2):139-145. doi: 10.1080/17512433.2022.2047934.
Kosmas CE, Bousvarou MD, Sourlas A, Papakonstantinou EJ, Peña Genao E, Echavarria Uceta R, Guzman E. Angiopoietin-Like Protein 3 (ANGPTL3) Inhibitors in the Management of Refractory Hypercholesterolemia. Clin Pharmacol. 2022 Jul 16;14:49-59. doi: 10.2147/CPAA.S345072.
Dingman R, Bihorel S, Gusarova V, Mendell J, Pordy R. Evinacumab: Mechanism of action, clinical, and translational science. Clin Transl Sci. 2024 Jun;17(6):e13836. doi: 10.1111/cts.13836.
Sosnowska B, Adach W, Surma S, Rosenson RS, Banach M. Evinacumab, an ANGPTL3 Inhibitor, in the Treatment of Dyslipidemia. J Clin Med. 2022 Dec 25;12(1):168. doi: 10.3390/jcm12010168.
Reeskamp LF, Millar JS, Wu L, Jansen H, van Harskamp D, Schierbeek H, Gipe DA, Rader DJ, Dallinga-Thie GM, Hovingh GK, Cuchel M. ANGPTL3 Inhibition With Evinacumab Results in Faster Clearance of IDL and LDL apoB in Patients With Homozygous Familial Hypercholesterolemia-Brief Report. Arterioscler Thromb Vasc Biol. 2021 May 5;41(5):1753-1759. doi: 10.1161/ATVBAHA.120.315204.
Marston NA, Zimerman A. Future of angiopoietin-like protein 3 inhibitors as a therapeutic agent. Curr Opin Lipidol. 2025 Dec 1;36(6):285-291. doi: 10.1097/MOL.0000000000001013.
Kersten S. Role and mechanism of the action of angiopoietin-like protein ANGPTL4 in plasma lipid metabolism. J Lipid Res. 2021;62:100150. doi: 10.1016/j.jlr.2021.100150.
Zhang R. ANGPTL3/8: one target, multiple lipid disorders. Trends Mol Med. 2025 Oct 29:S1471-4914(25)00241-2. doi: 10.1016/j.molmed.2025.10.003.
Cummings BB, Joing MP, Bouchard PR, Milton MN, Moesta PF, Ramanan V, Lane A, Hirman J, Trauger JW, Maratos-Flier E, Voznesensky A, Splawski I, Nimonkar AV, Flaherty MM, Yi BA, Meyers D, Huet F, Sahambi SK, Yates DP, Hom D, Hinder M, Basson CT, O'Donnell C, Siegelman ES, Garrett CE, Lehrer-Graiwer J, Juliano RA, Weiss EJ. Safety and efficacy of a novel ANGPTL4 inhibitory antibody for lipid lowering: results from phase 1 and phase 1b/2a clinical studies. Lancet. 2025 May 31;405(10493):1923-1934. doi: 10.1016/S0140-6736(25)00825-6. Epub 2025 May 15. Erratum in: Lancet. 2025 Jul 12;406(10499):134. doi: 10.1016/S0140-6736(25)01397-2.
Gaudet D, Gonciarz M, Shen X, Leohr JK, Beyer TP, Day JW, Mullins GR, Zhen EY, Hartley M, Larouche M, Konrad RJ, Benichou O, Ruotolo G. Targeting the angiopoietin-like protein 3/8 complex with a monoclonal antibody in patients with mixed hyperlipidemia: a phase 1 trial. Nat Med. 2025 Aug;31(8):2632-2639. doi: 10.1038/s41591-025-03830-4.
Canfora I, Pierno S. Hypertriglyceridemia Therapy: Past, Present and Future Perspectives. Int J Mol Sci. 2024 Sep 8;25(17):9727. doi: 10.3390/ijms25179727.
Olmastroni E, Galimberti F, Xie S, Casula M, Catapano A L, Effects of fibrates on lipid profile: a meta-analysis of randomized controlled trials, EAJ 2025; 1:6-16. doi: 10.56095/eaj.v4i1.103.
Yamashita S, Masuda D, Matsuzawa Y. Pemafibrate, a New Selective PPARα Modulator: Drug Concept and Its Clinical Applications for Dyslipidemia and Metabolic Diseases. Curr Atheroscler Rep. 2020 Jan 23;22(1):5. doi: 10.1007/s11883-020-0823-5.
Elbahloul MA, Elgadi A, Ramadan M, Mohamed Amine H, Fayed H, Kasser ME, Hussein A, Labieb F. Efficacy and safety of pemafibrate administration in patients with dyslipidemia: a systematic review and updated meta-analysis of randomized controlled trials. Ann Med Surg (Lond). 2025 Apr 22;87(6):3756-3767. doi: 10.1097/MS9.0000000000003264.
Kim KA, Kim NJ, Choo EH. The effect of fibrates on lowering low-density lipoprotein cholesterol and cardiovascular risk reduction: a systemic review and meta-analysis. Eur J Prev Cardiol. 2024 Feb 15;31(3):291-301. doi: 10.1093/eurjpc/zwad331. Erratum in: Eur J Prev Cardiol. 2024 Feb 15;31(3):373. doi: 10.1093/eurjpc/zwad368.
Arai H, Yamashita S, Araki E, Yokote K, Tanigawa R, Saito A, Furukawa D, Suganami H, Ishibashi S. Long-Term Effects of Extended-Release Pemafibrate Tablets on Dyslipidemia and Safety in Triglyceridemic Patients: A Phase 3, Multicenter, Randomized, Open-Label, Parallel-Group Study. J Atheroscler Thromb. 2025 Aug 1;32(8):1006-1026. doi: 10.5551/jat.65350.
Chukwurah MI, Miller M. Fibrates, Hypertriglyceridemia, and CVD Risk: Where Do We Stand After the PROMINENT Trial for Triglyceride Lowering? Curr Cardiol Rep. 2023 Sep;25(9):987-992. doi: 10.1007/s11886-023-01926-2.
Miller M. Pemafibrate and other triglyceride-lowering therapies to reduce risk of cardiovascular and metabolic disease. Curr Opin Cardiol. 2024 Jul 1;39(4):286-291. doi: 10.1097/HCO.0000000000001136.
Cicero AFG, D'Addato S, Borghi C. A Randomized, Double-Blinded, Placebo-Controlled, Clinical Study of the Effects of a Nutraceutical Combination (LEVELIP DUO®) on LDL Cholesterol Levels and Lipid Pattern in Subjects with Sub-Optimal Blood Cholesterol Levels (NATCOL Study). Nutrients. 2020 Oct 14;12(10):3127. doi: 10.3390/nu12103127.
Ardissino D, Colletti A, Pellizzato M, Pagliari G, Di Pierro F, Cravotto G. Short-Term Effect of Nutraceutical Fruit Juices on Lipid Metabolism in Patients with Acquired Hypercholesterolemia. Int J Mol Sci. 2023 Apr 16;24(8):7358. doi: 10.3390/ijms24087358.
Cicero AFG, Fogacci F, Banach M. Red Yeast Rice for Hypercholesterolemia. Methodist Debakey Cardiovasc J. 2019 Jul-Sep;15(3):192-199. doi: 10.14797/mdcj-15-3-192.
Jacobo-Velázquez DA. Functional Foods for Cholesterol Management: A Review of the Mechanisms, Efficacy, and a Novel Cholesterol-Lowering Capacity Index. Nutrients. 2025 Aug 15;17(16):2648. doi: 10.3390/nu17162648.
Millán J, Cicero AF, Torres F, Anguera A. Effects of a nutraceutical combination containing berberine (BRB), policosanol, and red yeast rice (RYR), on lipid profile in hypercholesterolemic patients: A meta-analysis of randomised controlled trials. Clin Investig Arterioscler. 2016 Jul-Aug;28(4):178-87. doi: 10.1016/j.arteri.2016.03.002.
Pérez-Martínez P, Ros E, Pedro-Botet J, Civeira F, Pascual V, Garcés C, Solá R, Pérez-Jiménez F, Mostaza JM. Functional foods and nutraceuticals in the treatment of hypercholesterolemia: Statement of the Spanish Society of Arteriosclerosis 2023. Clin Investig Arterioscler. 2023 Sep-Oct;35(5):248-261. English, Spanish. doi: 10.1016/j.arteri.2023.02.002.
Zhang M, Li R, Wang W X, Wang T Q, Huang T, Hua X W, Tang Y D, Genetic inhibition of angiopoietin-like protein 3, 4, and 8 on cardiovascular disease risk, European Heart Journal, Volume 46, Issue Supplement_1, November 2025, ehaf784.4325, doi: 10.1093/eurheartj/ehaf784.4325.
Powell J, Piszczatoski C. Bempedoic Acid: A New Tool in the Battle Against Hyperlipidemia. Clin Ther. 2021 Feb;43(2):410-420. doi: 10.1016/j.clinthera.2020.12.001.
Jokiniemi A, Magris M, Ritari J, Kuusipalo L, Lundgren T, Partanen J, Kekäläinen J. Post-copulatory genetic matchmaking: HLA-dependent effects of cervical mucus on human sperm function. Proc Biol Sci. 2020 Aug 26;287(1933):20201682. doi: 10.1098/rspb.2020.1682.
Katritsis DG, John RM, Latchamsetty R, Muthalaly RG, Zografos T, Katritsis GD, Stevenson WG, Efimov IR, Morady F. Left Septal Slow Pathway Ablation for Atrioventricular Nodal Reentrant Tachycardia. Circ Arrhythm Electrophysiol. 2018 Mar;11(3):e005907. doi: 10.1161/CIRCEP.117.005907.
Mansoor T, Rao BH, Gupta K, Parikh SS, Abramov D, Mehta A, Al Rifai M, Virani SS, Nambi V, Minhas AMK, Koshy SKG. Inclisiran as a siRNA Inhibitor of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9); Past, Present, and Future. Am J Cardiovasc Drugs. 2025 May;25(3):293-306. doi: 10.1007/s40256-024-00712-x.
Copyright (c) 2026 Agnieszka Bajkacz
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.
